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Abstract: Hypoxic–ischemic brain damage is an alarming health and economic problem in spite of
the advances in neonatal care. It can cause mortality or detrimental neurological disorders such
as cerebral palsy, motor impairment and cognitive deficits in neonates. When hypoxia–ischemia
occurs, a multi-faceted cascade of events starts out, which can eventually cause cell death. Lower
levels of oxygen due to reduced blood supply increase the production of reactive oxygen species,
which leads to oxidative stress, a higher concentration of free cytosolic calcium and impaired
mitochondrial function, triggering the activation of apoptotic pathways, DNA fragmentation and cell
death. The high incidence of this type of lesion in newborns can be partly attributed to the fact that the
developing brain is particularly vulnerable to oxidative stress. Since antioxidants can safely interact
with free radicals and terminate that chain reaction before vital molecules are damaged, exogenous
antioxidant therapy may have the potential to diminish cellular damage caused by hypoxia–ischemia.
In this review, we focus on the neuroprotective effects of antioxidant treatments against perinatal
hypoxic–ischemic brain injury, in the light of the most recent advances.
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1. Introduction
Perinatal hypoxic–ischemic encephalopathy (HIE) still continues to be an alarming health
and economic problem, being associated with approximately 25% of global neonatal deaths [1,2].
This condition affects 1.5 per 1000 newborns annually [3]. However, the incidence is even higher in
low- and middle-income countries, where 96% of the 1.15 million cases of neonatal encephalopathy
estimated in 2010 took place [1,4]. In fact, intrapartum hypoxia–ischemia (HI) is associated with an
estimated 30% of the cases of neonatal encephalopathy in developed countries and 60% of cases in
developing countries [3].
Thus, HIE is believed to be one of the most important causes of mortality and chronic disorders in
infants [5,6]. The different causes of HIE can happen before, during or after birth. Premature neonates
are particularly at risk of suffering HIE, with the incidence being a significant 60% higher [7,8]. Due to
the reduction of oxygen and glucose in the brain, newborns can die or suffer from severe neurological
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dysfunctions such as cerebral palsy, mental retardation, epilepsy, visual and hearing impairment,
learning and behavioral disabilities, attention deficits and hyperactivity [9–12].
The pathogenic mechanisms of HI injury have recently been classified into three phases: that
of primary energy failure due to the HI insult; a secondary phase, which is a consequence of
reoxygenation and reperfusion and, finally, a tertiary phase in which previous events can get worse
and inflammation become chronic [5,13–15] (Figure 1). Briefly, when the hypoxic–ischemic insult
occurs, there is a rapid depletion of ATP due to the decrease in oxidative phosphorylation. Although
the cell changes to anaerobic metabolism, this is energetically inefficient and results in the failure of the
ATP-dependent Na/K pump and accumulation of metabolites, such as lactic acid and hypoxanthine.
Then, a progressive membrane depolarization occurs, with an excessive accumulation of excitatory
amino acids on the extracellular side, as well as an excessive entry of water, sodium and calcium into
the cell. All these primary processes lead to cellular edema and early cell death. The second phase
is related to reoxygenation and reperfusion. The partial recovery of oxidative metabolism triggers
an increased production of radical oxygen species (ROS), higher levels of intracellular calcium and
mitochondrial dysfunction. There is also an increase in the expression of pro-inflammatory genes and
late cell death. Finally, previously mentioned harmful processes can be exacerbated in the tertiary
phase, which can last from days to months. While neurogenesis, synaptogenesis and axonal growth
are diminished, inflammation and epigenomic changes augment, leading to detrimental brain injury.
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Figure 1. Pathogenic mechanisms involved in neonatal hypoxia–ischemia. Primary energy failure
occurs immediately after the hypoxic–ischemic insult. After reperfusion, there is a secondary energy
failure, which can extend in duration from 6 to 48 h. Finally, the tertiary phase takes place and the
previous deleterious events can further exacerbate brain injury (from days to months). The up arrows
represent an increase while the down arrows show a decrease on the corresponding metabolite/process.
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2. Oxidative Stress and Endogenous Antioxidants
Perinatal hypoxic–ischemic injury causes devastating brain damage and there is little doubt about
the fact that oxidative stress is one of the mayor contributors to this. An excessive production of ROS
occurs, including radical species, such as superoxide and hydroxyl radicals, as well as non-radical
toxic species, such as singlet oxygen and hydrogen peroxide [16]. Not only are ROS overproduced, but
also reactive nitrogen species, with nitric oxide being the most detrimental, since this can significantly
enhance the toxicity of superoxide radicals [13].
The brain, apart from being the most metabolically active organ in the human body, maintains a
fragile redox homeostasis, because of its low antioxidant defense and high content of easily oxidizable
membrane lipids. Despite the fact that under physiological conditions the antioxidant enzyme system
is able to protect against cell injury, under asphyctic conditions it fails, with neurons being particularly
vulnerable to free radical damage [17]. The cellular enzymatic antioxidant defense system consists
of three enzymes: superoxide dismutase (SOD), which catalyzes the dismutation of the superoxide
radical to hydrogen peroxide (H2O2); glutathione peroxidase (GPx) and catalase, which catalyze the
reduction of H2O2 to water and oxygen [13] (Figure 2).
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Figure 2. Effects of antioxidant enzymes on free radicals in the neonatal brain. In the diagram, the cell’s
enzymatic antioxidant defense system, consisting of three enzymes is shown. Superoxide dismutase
(SOD) catalyzes the dismutation of the superoxide radical (O2−) to hydrogen peroxide (H2O2). Then,
glutathione peroxidase (GPx) together with catalase catalyze the reduction of H2O2 to water and
oxygen. In the absence of GPx and catalase, the O2− is converted to hydroxyl radical (OH−), which
can induce oxidative damage to the cell. GSH, glutathione; GSSG, glutathione disulfide. The black
arrows represent the mitigation or avoidance of the oxidative damage due to the antioxidant enzymes,
while the red arrows represent the free radical production in absence of an efficient antioxidant defense
system which leads to an oxidative damage process.
The infant brain is particularly susceptible to HI [18,19], because of its specific characteristics:
abundant unsaturated fatty acids, high rate of oxygen consumption, few antioxidants, high water
content, low myelinization, low concentration of antioxidant enzymes, higher concentrations of
free iron and oxygen-induced vasoconstriction [20–24]. The implication of ROS in the HI-induced
brain damage is irrefutable; for example, it has been clearly shown that plasma malondialdehyde, a
product of lipid peroxidation, and nitrate/nitrite levels were significantly higher in neonates with
HIE [25]. During reperfusion and reoxygenation, the antioxidant defense system is overwhelmed by
the oxidative stress, leading to further damage: lipid peroxidation, protein denaturation, inactivation
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of enzymes, DNA damage, release of calcium from intracellular stores and damage to the cytoskeletal
structure [26]. Hence, cell membrane are highly susceptible to free radical-induced peroxidation
because of their polyunsaturated fatty acids [25] particularly in the immature brain.
3. New Approaches to Antioxidant Therapy
Nowadays, therapeutic hypothermia has been established as a standard clinical procedure for
infants diagnosed with moderate to severe neonatal encephalopathy in the developed world [27],
supported by evidence from both animal studies and large-scale clinical trials in humans [28].
Numerous studies performed on animals have demonstrated that hypothermia is able to ameliorate
long-term brain injury in both the grey and white matter in rats [29] and to reduce brain cell death in a
piglet asphyxia model with cooling by 3.5 to 5 ◦C [30]. However, this study also reported that following
cooling by 8.5 ◦C cell death was increased in piglets, suggesting the potential detrimental effects of
excessive cooling and underlining the importance of research about the optimal cooling temperature.
Concerning the effects of hypothermia in humans, Jacobs et al. [31] reviewed 11 randomized
controlled human trials involving 1505 term and late preterm neonates with moderate or severe
encephalopathy and evidence of intrapartum asphyxia and concluded that cooling significantly
reduced the mortality rate, with the benefits outweighing the short-term adverse effects. Nevertheless,
therapeutic hypothermia is only partially effective, with almost 50% of treated infants having adverse
outcomes [32]. More specifically, in the United Kingdom, 45% of neonates have an adverse outcome
after HI despite hypothermia, with 25% dying and 20% developing cerebral palsy and other life-long
debilitating conditions [32]. Adjunct therapies for hypothermia are needed to enhance overall
protection and improve outcomes. Moreover, in low- and mid-resource settings where cooling is not
routine, alternative therapies may be important [33].
Various studies have shown that the efficacy associated with therapeutic hypothermia could
be increased by using a combination of treatments [27]. For example, Park et al. [34] found that
hypothermia augments the neuroprotective activity of mesenchymal stem cells derived from human
umbilical cord blood for neonatal HIE in male rats [34]. In addition, Lafuente et al. [35] reported
the additive protective effects of hypothermia and cannabidiol on excitotoxicity, inflammation and
oxidative stress, and on cell damage; the effects of combination therapy were greater than either
hypothermia or cannabidiol alone. Although multiple therapeutic strategies for the amelioration of
neonatal HIE have been investigated at the experimental level [5,36], the corresponding results have
not been as positive as expected. Since increased levels of oxidative stress, excitatory neurotransmitters
and inflammation occurring during the HI insult are considered to be the “deadly triad” leading to
brain damage [37,38], it is reasonable to assume that therapies aimed at preventing the damage caused
by all these processes may afford effective and even complete neuroprotection [37–39].
The developing neonatal brain is particularly vulnerable to oxidative stress because free-radical
scavenging systems have not yet matured, resulting in insufficient synthesis of antioxidant
enzymes/scavengers following injury [33]. As antioxidants can safely interact with free radicals and
terminate that chain reaction before vital molecules are damaged, it seems reasonable to assume that
exogenous antioxidant therapy may have the potential to reduce the associated cellular damage. In fact,
antioxidants might act at different steps of the damage: scavenging ROS, reducing the production
of free radicals, altering antiradical defenses, increasing the antioxidant levels and adding lipophilic
antioxidants into cell membranes [40]. For this reason, we review here the most recent advances
regarding antioxidant therapies for perinatal hypoxic–ischemic brain injury.
3.1. Allopurinol
Allopurinol is a chemical compound which is able to inhibit xanthine oxidase and acts as a
free radical scavenger. Free radical formation due to conversion of hypoxanthine into xanthine by
xanthine oxidase is very important during HI injury. In fact, during the first phase of HI when
cells shift to anaerobic metabolism, hypoxanthine accumulates, and during the reoxygenation phase,
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hypoxanthine is oxidized by xanthine oxidase and superoxide free radicals are produced [41]. This is
why the inhibition of xanthine oxidase by allopurinol is fundamental to avoid the propagation of ROS
production during the first phases of HI insult. Although allopurinol has scarcely been investigated
in animal models of HI brain injury, it has been shown to exhibit neuroprotective properties when
administered 15 min after inducing hypoxia–ischemia in 7-day-old (P7) Wistar rats at a high dose
(Zyloprim sodium, 135 mg/kg). It ameliorated brain injury by reducing the increase in the water
content in the ipislateral hemisphere and markedly decreasing atrophy, and it also reduced long-term
cerebral injury in immature rats [42,43]. More recently, the effects of allopurinol administration prior
to hypoxia on brain levels of adenosine and purine metabolites have been evaluated in a larger animal
model [44]. In the newborn piglet, allopurinol effectively inhibited xanthine oxidase and resulted in a
significant increase in brain tissue levels of adenosine and inosine under severe hypoxic conditions.
In spite of the paucity of research performed on animals, the number of human clinical trials
evaluating the efficacy of allopurinol against HIE is higher. However, the results obtained from these
studies are contradictory. On the one hand, some studies were not found to be as promising as
expected. Benders et al. [45] claimed that early postnatal allopurinol (Apurin, 40 mg/kg), administered
intravenously as soon as possible after birth asphyxia (about 4 h after birth) and 12 h later, does not
reduce the early reperfusion-induced free radical surge and does not improve short term outcome
after severe birth asphyxia, although the authors also pointed out that their sample size was too
small to exclude beneficial effects of early postnatal allopurinol treatment. Besides, Chaudhari and
McGuire [46] reviewed the available data about randomized or quasi-randomized controlled trials that
compared allopurinol vs. placebo in newborns with HIE, and they concluded that the available data
could not conclusively demonstrate the benefits of this compound, as much larger trials were needed.
On the other hand, other clinical trials have successfully demonstrated the neuroprotective effect of
this xanthine oxidase inhibitor in neonatal HIE. A high dose of allopurinol (40 mg/kg) has been found
to have beneficial effects on free radical formation, cerebral blood volume and electrical brain activity,
without toxic side effects [47]. Moreover, it has been proved that allopurinol (500 mg), intravenously
(i.v.) administered to the mother during fetal hypoxia crosses the placenta and lowers cord blood levels
of the brain injury marker S-100B, as well as nonprotein-bound iron concentrations [48]. Similarly,
in another trial, a group of grade I to III (mild to severe) asphyxiated infants were treated with
intravenous allopurinol (Apuria; 40 mg/kg/day) for 3 days (with the first dose within 2 h after
birth; total dose of 40 mg/kg administered in 30 min in two dosages for 3 days). Reduced serum
nitric oxide levels were observed, but high nitric oxide levels were found to be present in severely
asphyxiated infants. Additionally, the asphyxiated newborns treated with allopurinol had better
neurologic and neurodevelopmental outcomes at 12 or more months of age [49]. More recently,
Kaandorp et al. [50] found that neonatal allopurinol (Apurin) treatment may lower the risk of death or
severe disability in the long term (at 4–8 years of age) in moderately asphyxiated infants, indicating
long-term neuroprotective effects, and that neonatal treatment with high-dose allopurinol does not
have negative side effects in the follow-up of two randomized controlled trials, where infants received
40 mg/kg allopurinol (with an interval of 12 h) starting within 4 h after birth. Therefore, the majority
of the pilot studies indicate that allopurinol can exert long-term neuroprotection in human infants,
by reducing free-radical production and by acting as a free-radical scavenger and free iron chelator,
without having negative side effects when administered at high and repeated doses.
3.2. Erythropoietin
Erythropoietin (EPO) is a glycoprotein hormone that controls erythropoiesis and is also a
pleiotropic cytokine with a number of erythropoietic and non-erythropoietic roles [51]. EPO and
EPO-receptor (EPO-R) signaling are required for normal brain development [52]; in fact, during
gestation, there is an over-expression of both, and after birth their expression is diminished quickly in
human and rodent brains. After hypoxia, the expression of hypoxia inducible factor-1 (HIF-1) is stable,
and there is an increase in the expression of downstream targets and growth factors such as EPO and
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vascular endothelial growth factor [53,54]. Consequently, EPO and EPO-R are specifically expressed
by neurons, astrocytes and microglia [55].
EPO has been shown to be effective in adult rodent models of transient focal ischemia [56] and
permanent ischemia [55] by reducing infarct volume, and in embolic stroke by enhancing neurogenesis
and angiogenesis and improving neurological function [57]. Moreover, varying evidence points
to the efficacy of EPO against HIE in rodent and primate models, since this hormone exhibits
anti-inflammatory, anti-apoptotic and antioxidant effects [58,59], as detailed below. Nevertheless,
the cellular mechanisms by which EPO exerts neuroprotection are not completely understood [51].
In the Vannucci model, the neuroprotective effect of erythropoietin against brain damage has
been demonstrated under many different conditions: given as pre-treatment or as post-treatment and
with a single or multiple dose administration. However, not all the studies were carried out under
the same conditions, which hinders the extraction of clear conclusions. In the case of recombinant
human EPO (rhEPO) (300 units) administered intraperitoneally (i.p.) 24 h before hypoxia but repeated
(300 units) daily for an additional 2 days, reduced apoptotic cell death, partially mediated by the
activation of heat shock protein 27 in unsexed P7 Sprague Dawley rats, was reported [58]. When a
high dose rhEPO (1000 U/kg) was given intraperitoneally to 6-day-old Wistar rats immediately after
a HI insult, significantly decreased mean infarct volume [60], and significantly improved long-term
neurobehavioral achievements, as well as significantly diminished brain injury, in particular spared
hippocampal CA1 neurons, were found [61]. However, Fan et al. [62] reported that rhEPO (Eprex; i.p.,
5 or 20 kU/kg at 0, 24, and 48 h after HI) was not neuroprotective at a histological level in a HI
model using P9 mice (C57B1/6 J), when determined 24 h after the last EPO treatment (72 h after HI).
In contrast, long-term improvement in sensorimotor function, striatum atrophy, hippocampal lesions,
and white matter injury were observed when using 5 kU/kg EPO, but curiously only in female animals.
These authors suggested that EPO presents an inverted U-shaped dose–response curve, since the
beneficial effects of the lower EPO concentration were stronger and lasted longer than those of a higher
dose. These results were in accordance with those of Kellert et al. [63] who reported that three doses of
5000 U/kg subcutaneous rhEPO beginning immediately after the injury is optimal because it limits
total drug exposure and provides maximal benefit.
Concerning the time of delivery, Alexander et al. [64] performed a study designed to assess the
effectiveness of immediate and delayed administration of EPO on long-term behavioral and histological
outcomes in P7 male Wistar rats with early HI injury. Results from that study showed a therapeutic
benefit of EPO when given immediately following induction of HI injury, with diminished benefits
from a 60 min delayed injection of EPO, and no protection following a 180 minute delayed injection.
However, they used a single intraperitoneal injection schedule (1000 U/kg), whereas according to the
majority of articles, a repeated dosage of EPO is required for protection to become evident.
In other rodent models of hypoxic–ischemic brain injury, rhEPO has also demonstrated its
neuroprotective properties. Delayed erythropoietin therapy (1000 U/kg per dose × three doses)
improves histological and behavioral outcomes at one month following transient neonatal stroke
induced by transient middle cerebral artery occlusion for 3 h in P10 Sprague-Dawley rats [65]. These
results suggest that delayed EPO therapy may provide a late treatment alternative for early brain
injury. Similarly, in a model of transient middle cerebral artery occlusion, multiple doses of rhEPO
(R&D Systems; 1000 U/kg, at reperfusion, 24 h, and 7 days later) increased the neurogenesis and
oligodendrogliosis of subventricular zone precursor cells in P7 Long Evans rats [66]; it also sustains
cognitive function and brain volume after neonatal stroke in P10 Sprague-Dawley rats [67]. In this
model as well, immediately upon reperfusion, a single dose of rhEPO (5 units per gram of body
weight) preserved brain tissue and decreased infarct volume 6 weeks after injury; it also increased
the percentage of newly born neurons in the injured areas. Both pre-treatment (one hour before) and
post-treatment (immediately after insult, followed by additional injections at 24 and 48 h post-insult)
with rhEPO (5 U/g) ameliorates neonatal HI-induced neurobehavioral deficits, neuroinflammation,
and hippocampal injury in the juvenile rat model of HI (P5), which is relevant to immature human
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infants [68]. rhEPO also protected against white matter damage in a preterm equivalent neonatal HI
model in two-day-old rats [69]. Furthermore, postnatal recombinant erythropoietin (2000 U/kg/dose,
once a day from postnatal P1 to P5) was found to mitigate impaired cerebral cortical development
following subplate loss [70] and promote oligodendrocyte development [71] in a prenatal transient
systemic HI model performed on embryonic day 18.
The effectiveness of EPO in combination with hypothermia has been demonstrated in a term
nonhuman primate model of perinatal asphyxia, based on umbilical cord occlusion for 15 to 18
minutes. These injured Macaca nemestrina received rhEPO (Epogen; either EPO 3500 U/kg × one
dose i.v. followed by three i.v. doses of 2500 U/kg given at 30 min, 24 h, 48 h and 7 days; or EPO
1000 U/kg/day i.v. × four dosages at 30 min, 24 h, 48 h and 7 days) and they also underwent also
hypothermia, that started by the third hour of life and lasted 72 h (33.5 ◦C). These treated macaques
presented a longer survival rate without moderate-severe cerebral palsy, preserved cerebellar growth
rates, and exhibited improved neurocognitive behavioral scores after perinatal asphyxia [72]. As the
safety and efficacy of multiple EPO doses against HIE have been demonstrated in rodent and primate
models, some small human clinical trials have been carried out. Zhu et al. [73] showed how repeated
low-dose rhEPO treatment (Roche Diagnostics GmbH) reduces the risk of disability for infants with
moderate HIE, improving neurologic outcomes, without apparent side effects. Elmahdy et al. [74]
found that the administration of rhEPO (Eprex; 2500 IU/kg, subcutaneously, daily for 5 days) in
neonates suffering mild/moderate HIE decreased endogenous NO production, reduced seizures, and
alleviated neurodevelopmental disorders to 6 months of age. Similarly, Wu et al. [75] reported that
multiple doses of EPO (up to 2500 U/kg, i.v.) given in conjunction with hypothermia are well tolerated
in newborns with HIE. Rogers et al. [76] similarly declared that a high dose of EPO in combination with
hypothermia does not worsen long-term outcomes, and what is more, this study provided additional
confirmation that EPO does not have side effects, at least under these specific conditions. More recently,
Wu et al. [77] reported that high doses of EPO given with hypothermia for HIE may result in less brain
injury as assessed with magnetic resonance imaging (MRI) and improved motor function in a 1-year
follow-up phase II double-blinded, placebo-controlled trial. Therefore, these clinical trials also provide
evidence supporting the safety and preliminary efficacy of repeated or high doses of EPO in humans
3.3. Resveratrol
Resveratrol (3,5,4′-trihydroxystilbene) is a polyphenol produced by different plant species, such
as grapevines, pines and pomegranates, and whose most common dietary source is red wine.
This flavonoid is made up of two aromatic rings attached by a methylene bridge. Because of
its anti-oxidative, anti-apoptotic and anti-inflammatory effects, resveratrol has been found to be
neuroprotective [78–80]. The protective effects of resveratrol against brain injury caused by stroke in
a middle cerebral artery occlusion model (MCAO) in adult rodents have been investigated in depth
and clearly demonstrated [81–85]. The mechanisms of action of this polyphenol in stoke are related
to the reduction of oxidative stress by inhibiting xanthine oxidase and preventing the production of
hypoxanthine, xanthine and oxygen radicals [83] as well as by increasing the levels of malondialdehyde
and reduced glutathione [85]. Likewise, resveratrol also improves brain energy metabolism [83,84]
by restoring ATP content and the activity of mitochondrial respiratory complexes [84]. Although
research studies in rodent models of neonatal brain injury are not as abundant as in adult stroke
models, they strongly support the safety and efficacy of resveratrol for improving histological and
functional outcomes after hypoxia–ischemia in neonates, even if the mechanisms of its actions are not
completely understood.
Resveratrol, when administered before the HI event, was found to be a potent protective agent
that diminished tissue loss (Figure 3) and consequently infarct area both in rats and mice [86–88].
It also preserved myelination and minimized the astroglial reactive response [86,87]. Additionally,
its neuroprotective effects were found to be long lasting because it was able to improve long-lasting
cognitive deficits induced by hypoxia–ischemia [86,87]. Both non-spatial and spatial working
Int. J. Mol. Sci. 2017, 18, 265 8 of 22
memories, assessed by different behavioral tests, were found to be significantly improved in
resveratrol-treated neonatal rodents [86–88], and these findings might be associated with the
preservation of gray and white matter, especially at the level of the cortex and the hippocampus.
The beneficial effects of resveratrol to recover the alteration of auditory-evoked potentials and reduce
morphological damage in the inferior colliculus after rat perinatal asphyxia have also been reported [89].
Perhaps one of the best known mechanisms of action of resveratrol is that of apoptosis prevention.
West et al. [88] reported that caspase-3 activation is minimized by resveratrol. Likewise, it has also
been proposed that one of the mechanisms for this neuroprotection may be related to the maintenance
of the mitochondrial state, by protecting the integrity of the inner membrane and the transmembrane
potential, and by decreasing ROS production [86,89].
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resveratrol post-treatment can alleviate mild HI injury, but not severe or moderate injury. So 
increasing the concentration or repeating the dose over time could potentially result in 
neuroprotection against severe HI brain damage. 
Regarding the combination of resveratrol and the currently employed clinical treatment of HIE, 
Toader et al. [93] found that combined therapy had a neuroprotective effect in Wistar rats, 
significantly influencing oxidative stress parameters, particularly malondialdehyde levels. As 
resveratrol has been found to protect against stroke in neonatal rats and mice as well as in adults, it 
could potentially be considered for further investigations in large animal models, focusing on 
identifying the optimal dose and timing of administration to use it as a post-treatment, which is 
clinically more relevant. 
Figure 3. Representative stereomicroscopic photographs of rat brain sections (interaural distance
5.40 mm and bregma −3.60 mm) stained with Nissl at P14 from different experimental groups: (A) the
control group; (B) in the hypoxia–ischemia (HI) group, pups underwent permanent left common
carotid artery occlusion and, after two hours of recovery, they were asphyxiated for 135 min in 8% O2;
(C) the HI group pretreated with resveratrol (20 mg/kg), which was intraperitoneally administered
10 min before hypoxia [86]; and (D) the HI group pretreated with docosahexaenoic acid (1 mg/kg)
injected intraperitoneally 10 min before hypoxia [90]. The brain from the HI group presented an evident
loss of tissue in the ipsilateral side, while brains pretreated with either resveratrol or docosahexaenoic
acid were similar to the control brain, without obvious histological signs of infarct. Scale bar: 2.5 mm.
In contrast, there are some controversial results regarding resveratrol post-administration efficacy.
While Arteaga et al. [86] and West et al. [88] did not observe any signs of neuroprotection with
resveratrol administered after hypoxia–ischemia in rodents, Karalis et al. [87] did. However, this
discrepancy is likely due to the use of different durations of hypoxia (2 h and 15 min for Arteaga et al.,
versus 1 h for Karalis et al.) and to the use of different doses of resveratrol (20 mg/kg in the case
of Arteaga et al. and West et al., versus 90 mg/kg for Karalis et al.), because of the dose-dependent
effects in this animal model [88,91,92]. Hence, Arteaga et al. [86] proposed that low doses of resveratrol
post-treatment can alleviate mild HI injury, but not severe or moderate injury. So increasing the
Int. J. Mol. Sci. 2017, 18, 265 9 of 22
concentration or repeating the dose over time could potentially result in neuroprotection against severe
HI brain damage.
Regarding the combination of resveratrol and the currently employed clinical treatment of HIE,
Toader et al. [93] found that combined therapy had a neuroprotective effect in Wistar rats, significantly
influencing oxidative stress parameters, particularly malondialdehyde levels. As resveratrol has been
found to protect against stroke in neonatal rats and mice as well as in adults, it could potentially be
considered for further investigations in large animal models, focusing on identifying the optimal dose
and timing of administration to use it as a post-treatment, which is clinically more relevant.
3.4. Omega-3 Fatty Acids
Omega-3 fatty acids are polyunsaturated fatty acids (PUFA) with a double bond (C=C) at the
third carbon atom from the end of the carbon chain, hence the name “Ω-3”. As mammals are unable to
synthesizeΩ-3 fatty acids, they have to obtain them through diet, with marine algae and phytoplankton
being their primary sources. The three types of Ω-3 fatty acids involved in human physiology are
α-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and each of
these has have been found to exert neuroprotective effects against brain injury induced by experimental
stroke in adult and neonatal animal models.
In adult models of ischemia, different Ω-3 fatty acid family members have demonstrated their
efficacy. Both oral and intravenous supplementation of ALA improved spatial learning and memory
after stroke and this cognitive improvement is correlated with higher survival of hippocampal
neurons [94–97]. Regarding EPA, Ueda et al. [98] established the positive effect of ethyl-EPA on ischemic
brain damage following transient focal cerebral ischemia in rats and Okabe et al. [99] demonstrated
that EPA prevents memory impairment after ischemia by inhibiting both the inflammatory response
and oxidative damage after cerebral ischemia in gerbils.
Likewise, DHA has also shown very optimistic results in this regard, being the most investigated
Ω-3 fatty acid. Both pretreatment [100] and post-treatment with DHA [101–104] are efficient against
experimental stroke in adult rats. Similarly, both DHA and its bioactive mediator neuroprotectin D1
improve neurological deficits and reduce infarct size in aged animals [105,106]. Furthermore, DHA
complexed to 25% human albumin elicits high-grade neurobehavioral and histological neuroprotection
in transient focal and permanent cerebral ischemia in young and aged rats [105,107–109].
Concerning neonatal HI brain injury, only Mucci et al. [110] demonstrated how flaxseed
consumption, rich in DHA’s precursor α-linolenic acid, during gestation and lactation, was able
to mitigate brain mass loss and to improve spatial memory and motor hyperactivity. As far as
we know, there is no more evidence about the effects of ALA in neonatal models. Similarly, the
neuroprotective effects of EPA when given alone, do not appear to have been investigated, with the
exception of its administration in combination with DHA [111,112]. Zhan et al. [111,112] reported
that Ω-3 PUFA acid administered as a dietary supplement (DHA + EPA) to pregnant female rats,
starting the second day of pregnancy until 14 days after parturition, confers long-term neuroprotection
against neonatal hypoxic–ischemic brain injury by attenuating microglia-mediated inflammatory
responses through an NF-κB-dependent mechanism [111] and inhibits neuronal cell death by
promoting phosphatidylserine formation and Akt signaling [112]. Indeed, both Williams et al. [113]
and particularly Mayurasakorn et al. [114] found that triglyceride emulsions of DHA (tri-DHA) but
not tri-EPA are neuroprotective when administered immediately after HI injury in neonatal mice.
As in adult models of stroke, DHA has been the most investigated Ω-3, perhaps because it is
the major polyunsaturated fatty acid in the adult mammalian brain, where it constitutes more than
30% of the total phospholipid content of cellular membranes. DHA is able to reduce infarcted area
under a variety of schedules. When administered as a pretreatment complexed to 25% human albumin
(1 mg/kg), besides reducing cerebral damage at the level of the middle hippocampus [90,115] (Figure 3),
DHA preserves neurons and myelin and diminishes the astroglial reactive response and microglial
activation [90]. DHA is also able to recover the alteration of auditory-evoked potentials and reduce
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morphological damage in the inferior colliculus after rat perinatal asphyxia [89]. Likewise, positive
results were obtained when two doses of n-3 triglycerides (containing both DHA and EPA) [113] and
when triglyceride emulsions of DHA were given immediately after HI injury in mice [114]. Post-HI
administration of tri-DHA significantly increased DHA content and preserved Ca2+ buffering capacity
in cerebral mitochondria, ameliorated oxidative brain injury and increased DHA derived bioactive
metabolites in brain [114]. On the other hand, Berman et al. [116] reported that when DHA is given
15 min after HI, the treatment improves forepaw placing, but it is not able to reduce brain injury, in
spite of the dosage (DHA 1, 2.5, or 5 mg/kg). It has been proposed that DHA for neuroprotection
appears to have a reverse dose dependency, with more favorable results being found with low and
moderate doses [102,116]. One of the reasons why DHA did not work as a post-treatment might be
that multiple DHA doses are required, as in the work of Mayurasakorn et al. [114], where the first dose
was administered immediately after HI and the second dose 1 h later. The neuroprotective effects of
DHA are long lasting since it ameliorates long-term cognitive impairments related to memory caused
by neonatal hypoxia–ischemia in rats [90,111,114,117]. This effect has been observed both when DHA
is given prior to and after the injury, and also when it is given as a maternal supplementation starting
before the HI injury was induced at P7 and maintaining the Ω-3 PUFA-enriched diet seven days more
after that. One of the proposed mechanisms of action of this neuroprotection may be related to the
maintenance of mitochondrial function [89,90,114].
Taken as whole, DHA seems to be a promising candidate to use as an add-on treatment in
combination with the standard therapy of hypothermia for reducing the brain damage induced by
HI, due to its well-established safety record and its ability to readily cross the blood–brain barrier.
In this sense, Berman et al. [118] demonstrated that DHA post-treatment (2.5 mg/kg complexed to 25%
albumin) and brief delayed hypothermia (3 h, 30 ◦C) confers markedly improved sensorimotor function,
but only modestly reduced tissue injury in a neonatal rat asphyxia model. Unfortunately, these authors
did not clarify either the cellular or molecular mechanisms whereby DHA and hypothermia act in
concert to moderately attenuate brain injury and preserve sensorimotor function, and it is not clear if the
combination of both confers additive or synergistic neuroprotection. Thus, one of the next challenges
in the future should be to determine the appropriate dosage to use in post-treatment in combination
with hypothermia and to fully understand the relevant mechanisms of action, since the potential of
DHA as an effective therapeutic candidate for reducing ischemia-induced neurodegeneration in the
neonate continues to hold promise.
3.5. N-Acetyl-L-cysteine
N-Acetyl-L-cysteine (NAC) is a well-known and potent thiol-containing antioxidant. It is also a
scavenger of oxygen radicals and a precursor of glutathione. NAC is able to scavenge ROS, to restore
glutathione levels, to mitigate redox potential, to reduce apoptotic cell death and to diminish both
inflammatory cytokines and inducible nitric oxide synthase in an adult rat stroke model [119,120].
Additionally, pretreatment with NAC (i.p., 150 mg/kg given 30 min before) increased HIF-1α protein
levels and its target proteins EPO and glucose transporter 3, in the ipsilateral hemispheres of rodents
subjected to 90 min MCAO and 24 h reperfusion, indicating that HIF-1α might take part in NAC´s
protection in stroke [121].
In the same line, NAC has been demonstrated to attenuate HI brain injury in neonatal rats when
administered either alone [122] or in combination with systemic hypothermia [123,124]. When given
alone, its administration (100 mg/kg), 30 min prior to carotid artery occlusion surgery at P7 and
once a day up to P44, also recovered motor functions and mitigated the demyelination process in the
corpus callosum of neonatal HIE animals [122]. Moreover, when hypothermia was used in combination
with NAC (50 mg/kg) administration by intraperitoneal injection daily until rat sacrifice (at 3 week
of age), resulted in improvements in infarct volume, myelin expression and functional outcomes after
focal HI injury [124]; moreover, inducible nitric oxide synthase expression and caspase-3 activation
in the injured hemisphere were significantly decreased compared to cases treated with hypothermia
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alone, but only in female rats. When NAC was continued for 6 weeks, starting 1 h after initiation
of hypothermia, significant improvement in long-term neuromotor outcomes over hypothermia
treatment alone was also observed [123]. The administration of multiple doses of NAC (200 mg/kg)
provided marked neuroprotection in a model that combines infection/inflammation and HI. This was
associated with the reduction of isoprostane activation and nitrotyrosine formation, with the increase
of the levels of the antioxidants glutathione and thioredoxin-2, and with the inhibition of caspase-3,
calpain, and caspase-1 activation [125]. NAC has also been shown to exhibit neuroprotection in larger
animal models. However, to date, no pilot studies have been carried out in newborn human babies.
Post-resuscitation administration of NAC (20 or 100 mg/kg/h) abolished the increased concentration
of cerebral hydrogen peroxide and oxidized glutathione levels as well as lipid peroxidation in newborn
piglets [126]. Likewise, when it was given in a bolus of 3 mL/kg and followed by a 2 mL/kg/h infusion
for 4 h, it significantly reduced cerebral oxidative stress by suppressing hydrogen peroxide but not
NO production, improved cerebral perfusion and reduced brain lactate accumulation in moderately
hypoxic newborn piglets [127].
3.6. Deferoxamine
Deferoxamine (DFO), a bacterial siderophore produced by Streptomyces pilosus, chelates free iron
thereby preventing hydroxyl formation via the hydrogen peroxide-driven Fenton reaction. DFO
has several medical uses; it acts by removing excess iron in the bloodstream and thus by reducing
damage to organs [128]. In an in vitro model of ischemia, it has been found that DFO ameliorates
neuronal death after oxygen and glucose deprivation, and that this neuroprotection by DFO is, in
part, eliminated by blockade of HIF-1, suggesting that DFO protects through iron chelation and HIF-1
induction [129]. As DFO can cross the blood–brain barrier, different research groups have assessed
and then demonstrated the effectiveness of this antioxidant against HI brain injury in different animal
models. DFO was found to have neuroprotective properties in both postnatal day 7 rats, by decreasing
the levels of excitatory amino acids and by improving histological outcome in the hippocampus when
administrated immediately after HI (subcutaneous injection of 150 mg/kg) [130], and in P7 mice when
administered 10 min and 24 h after the injury (100 mg/kg, subcutaneously) [131]. Accordingly, in
newborn lambs, DFO effectively lowered free iron in cortical brain tissue and plasma [132], preserved
carotid artery flow, relative cerebral O2 metabolism and electrocortical brain activity [133]. Moreover,
it maintained cortical cell membrane activity of Na+, K+-ATPase during early reperfusion after severe
HI (2.5 mg/kg, i.v.), pointing to a reduction of free radical formation by DFO [134]. DFO has also been
found to be an effective therapeutic agent for reperfusion injury in the brain of newborn piglets after
neonatal hypoxia–ischemia (12.5 mg/kg/day) by ameliorating cerebral energy status and the water
T2 values [135]. Despite these positive results, the benefits of deferoxamine have never been tested in
clinical trials with human infants presenting with HIE.
3.7. Melatonin
Melatonin is a naturally occurring hormone that regulates the circadian rhythm. Its neuroprotective
effects against neonatal HIE have been investigated in depth due to its potent antioxidant
properties [136,137]; it does not have any pro-oxidant effect with other antioxidants nor does it
interference with other drug actions [138]. This indolamine acts as a direct scavenger, being able to
remove free radicals [139,140], and it can also generate products in a scavenger cascade, which may
collectively eliminate up to ten free radicals [140]. Melatonin can also act as an indirect antioxidant
through the activation of some of the most important antioxidant enzymes [141], the improvement
of mitochondrial efficiency [142], the stimulation of gene expression and through the enhancing of
the antioxidant effect of a variety of substances [143]. In addition, this hormone can act by inhibiting
adhesion molecules and by reducing polymorphonuclear leukocyte infiltration and inflammatory
activation [136].
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Melatonin has been shown to exert significant benefits in animal models of HIE. It has the
capacity to reduce infarct volume when administered either before or after injury in rats [144–147]
and to increase the number of morphologically well-preserved neurons in the most affected areas
of the brain, i.e., in the hippocampus and parietal cortex [144,148,149]. Similarly, it also prevents
morphopathological changes at the level of the inferior colliculus, which is correlated with the recovery
of the functional changes of the auditory pathway caused by the HI insult [89]. Besides, melatonin
is not only able to reduce neuronal damage but also white matter demyelination at the level of the
mid-dorsal hippocampus, thalamus and brainstem [89,144,150] and reactive astrogliosis at the level of
the mid-dorsal hippocampus, cortex and brainstem [89,144,150,151].
In some of these studies, a repeated dose has shown optimal results [144–147], and the
concentration of 15 mg/kg melatonin starting at 5 min after the HI event and repeated after 24 and 48 h
was found to be the most effective. These results suggested that melatonin acts dose-dependently as a
neuroprotectant when administered both before and after the ischemic insult [147]. Another important
aspect of the neuroprotective effects of melatonin is that they are long-lasting as both brain injury and
behavioral outcomes improved even up to adulthood [147].
The potent antioxidant properties of the main secretory product of the pineal gland have
been extensively researched in this model. Maternal melatonin administration within 1 h after an
ischemic/oxidative episode can prevent ischemia/reperfusion-induced oxidative cerebral damage
in neonatal rats [149]. Moreover, it also reduced the levels of desferoxamine-chelatable free
iron, isoprostanes, and neuroprostanes, all of which are oxidative stress biomarkers [147,151,152].
Furthermore, treatment with melatonin reduces nitrotyrosine expression in proteins, the formation of
which can result in malfunction of these proteins. It also inhibits monocyte infiltration and microglial
activation [151]. In an umbilical cord occlusion model in fetal sheep, melatonin has also been found
to be able to abolish lipid peroxidation [153], to attenuate the production of 8-isoprostanes, and the
activation of microglia [136]. Prevention of increased free radical production after intrauterine asphyxia
in fetal sheep has been also shown [136]. These results indicate the important neuroprotective role
of melatonin in reducing oxidative damage resulting from HI, and one of the possible mechanisms
of action might be its reduction of endoplasmic reticulum stress and the preservation of sirtuin 1
expression in newborn rat neurons after hypoxia–ischemia [154].
Closely related to oxidative stress, mitochondrial impairment is a key feature underlying neonatal
HI. Melatonin administration to pregnant rats may prevent ischemia/reperfusion-induced oxidative
mitochondrial damage in the premature fetal brain [155]. Indeed, it protects against oxidative
mitochondrial damage induced in rat placenta by ischemia and reperfusion as well [156]. However, the
group of Berger et al. [157] recently found no improvement of neuronal metabolism in the reperfusion
phase with melatonin treatment after HI brain injury in the neonatal rat, suggesting that melatonin
treatment may not have protective effects on neuronal metabolism, since this protection has only been
reported in astrocytic mitochondrial metabolism.
Taken as a whole, there is convincing evidence that melatonin has beneficial effects against
perinatal brain damage in animals. Similarly, novel melatonin derivatives, such a Neu-P11 (a MT1/MT2
receptor agonist), have also been found to be neuroprotective in brain ischemia related models [158].
The neuroprotection obtained by the combination of melatonin with therapeutic hypothermia after
transient hypoxia–ischemia in a piglet model of perinatal asphyxia has already been shown [27].
Intravenous melatonin administration (5 mg/kg/h over 6 h beginning 10 min after resuscitation and
repeated at 24 h) increases the beneficial properties of cooling by alleviating energy metabolism in the
brain (deep grey matter lactate/N-acetyl aspartate and lactate/creatine). Indeed, it did not change the
heart rate or arterial blood pressure, inotropes, blood electrolytes, or glucose and lactate levels during
or after treatment. When melatonin and therapeutic hypothermia are given together, the benefits of the
combination were also related to elevated ATP levels in the brain and to the reduction in the number of
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive cells in the thalamus,
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white matter, internal capsule, putamen and caudate, as well as to the reduction in levels of caspase-3
in the thalamus [27].
These results lay the groundwork for future clinical studies in infants; in fact, melatonin’s
neuroprotection against perinatal asphyxia has already been demonstrated in a randomized controlled
pilot study [159]. The newborns who received five daily enteral doses of melatonin (10 mg/kg) in
combination with hypothermia, had fewer seizures and less white matter abnormalities and presented
improved survival without neurological or developmental abnormalities at 6 months. Therefore, in
the light of the most recent studies, melatonin could represent a potentially safe approach to perinatal
brain damage in humans.
3.8. Other Antioxidants
A number of other antioxidants have also demonstrated their potential beneficial effects against
HIE, but we would like to highlight in particular magnesium sulphate (MgSO4) and nicotine.
Magnesium sulphate, an inorganic salt, is the main preparation of intravenous magnesium and
it has several medical uses. Magnesium minimizes excitotoxic injury by binding to the magnesium site
on the N-methyl-D-aspartate glutamate channel in vitro [160]. In premature fetal lambs affected by
partial occlusion of the umbilical cord, MgSO4 preserves the HI-induced diminishment in the levels
of the S-100 protein and it did not alter the expression of endothelial tight junction molecules [161].
The authors suggested that MgSO4 neuroprotective effects are due to the restoration of blood–brain
permeability. In P7 rats that underwent HI and received MgSO4, sensorimotor deficits and brain
injury were reduced [162]. In contrast, Galinsky et al., [160] in their review about the effectiveness of
maternal magnesium sulfate in extensive controlled trials, suggested that magnesium is not consistently
neuroprotective for perinatal HI models in term-equivalent preclinical studies.
Nicotine, a nicotinic acetylcholine receptor agonist, is known to have antioxidant functions. When
intraperitoneally administered two hours before the HI insult in P7 rats, nicotine (1.2 mg/kg) is able
to recover the alteration of auditory-evoked potentials and reduce morphological damage in the
inferior colliculus [89], but it scarcely altered the expression of immediate early genes compared to the
control group [150]. Although, it has not been deeply investigated in HIE, nicotine may prove to be a
promising candidate for further evaluation in the light of the recent results.
4. Conclusions
There is convincing evidence in the above mentioned literature that different antioxidant
treatments have the potential to be therapeutically effective in different animal models of HIE.
Nevertheless, we would like to point out that none of the mentioned antioxidants reviewed have been
approved either by the Unites States Food and Drug Administration or by the European Medicine
Agency. Most of the revised antioxidants do not present negative side effects at high doses and almost
all of them seem to be neuroprotective both when used as pre-treatments or post-treatments. However,
for some of them, multiple doses are required to achieve optimal protective effects. Although the
mechanisms by which antioxidants exert neuroprotection are not fully understood, in part also because
of the complexity of neonatal hypoxic–ischemic pathophysiology, these studies have demonstrated the
high potential of these antioxidants as efficient therapeutic agents for the reduction of brain damage in
newborns. The most promising candidates seem to be the antioxidants that have already been found
to be neuroprotective in human trials, i.e., the erythropoietin and melatonin, since their beneficial
effects against HIE have been proved when they are used as an add-on treatment in combination with
hypothermia. Additionally, these antioxidants exhibit anti-inflammatory and anti-apoptotic properties
as well. The next challenging goal will be to adjust the optimal dosage of these antioxidants when
given in combination with hypothermia, so that larger neuroprotective effects can be exerted in the
human brain. To this end, additional randomized controlled human trials will need to be performed.
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